Geneva, May 28 -- International Clinical Trials Registry received information related to the study (ACTRN12625000446460) titled 'A healthy volunteer study to test a new drug, CNT2130' on May 13.
Study Type: Interventional
Study Design:
Purpose: Treatment
Allocation: Randomised controlled trial
Masking: Blinded (masking used)
Assignment: Parallel
Primary Sponsor: Centaurus Therapeutics Pty Ltd
Condition:
Diabetic Nephropathy
Diabetic Nephropathy
Renal and Urogenital - Kidney disease
Metabolic and Endocrine - Diabetes
Intervention:
CNT2130 is an oral capsule that will be administered in 3 groups. Group 1 will administer a dose of 15 milligrams (mg). Group 2 will administer a dose of 45 mg, and Group 3 will administer a dose of 90 m...